Eczacılık Fakültesi

Akademik Kadro

Prof. Dr. Süreyya Ölgen

Prof. Dr.
Süreyya Ölgen

Farmasotik Kimya

Çalışma Alanları

  • Sağlık Bilimleri Temel Alanı
  • Farmasotik Kimya
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Investigating the Activity of Indole-2-on Derivative Src kinase inhibitors against Chronic Myeloid Leukemia Cells, 2023
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Design and Synthesis of Novel Indole Derivatives as Tyrosine Kinase Inhibitors, 2022
  • Drug Repurposing in Cancer Therapy: Approaches and Applications, ISBN: 0000000, 2020
  • Drug Repurposing in Cancer Therapy: Approaches and Applications, ISBN: 0000000, 2020
  • Drug Repurposing in Cancer Therapy: Approaches and Applications, ISBN: 0000000, 2020
  • Drug Repurposing in Cancer Therapy: Approaches and Applications, ISBN: 0000000, 2020
  • Drug Repurposing in Cancer Therapy: Approaches and Applications, ISBN: 0000000, 2020
  • Postdoctoral Fellow, 1998
  • Postdoctoral Scientist, 2000
  • Visiting Professor, 2002
  • Visiting Professor, 2003
  • Visiting Scientist, 2003